A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of VIS410 in Subjects With Uncomplicated Influenza A Infection
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Oct 2017
At a glance
- Drugs VIS 410 (Primary)
- Indications Influenza A virus infections
- Focus Adverse reactions
- Sponsors Visterra
- 10 Oct 2017 This trial has been completed in Bulgaria.
- 05 Oct 2017 According to a Visterra media release, top-line results are expected in early 2018.
- 26 Jul 2017 Planned End Date changed from 1 Sep 2017 to 1 Nov 2017.